IL33 and irritable bowel syndrome: This relationship illustrates the limitations of studies on particular inflammatory factor signaling pathways, and suggests the need to evaluation of “when” and “how” the IL-33/ST2 signaling when exploring novel IL-33-targeting biological agents in the therapeutic armamentarium against IBD in the future (Aggeletopoulou et al., 2022).